58
Participants
Start Date
October 31, 2014
Primary Completion Date
April 30, 2016
Study Completion Date
April 30, 2016
Alemtuzumab GZ402673
Pharmaceutical form:concentration for solution Route of administration: intravenous infusion
cetirizine
Pharmaceutical form:tablet Route of administration: oral
ranitidine
Pharmaceutical form:tablet Route of administration: oral
methylprednisolone
Pharmaceutical form:tablet Route of administration: oral
methylprednisolone
Pharmaceutical form:solution Route of administration: intravenous
aciclovir
Pharmaceutical form:tablet Route of administration: oral
esomeprazole
Pharmaceutical form:tablet Route of administration: oral
ibuprofen
Pharmaceutical form:tablet Route of administration: oral
paracetamol
Pharmaceutical form:tablet Route of administration: oral
Investigational Site Number 056001, Brussels
Investigational Site Number 056002, Bruges
Investigational Site Number 250009, Dijon
Investigational Site Number 724002, Madrid
Investigational Site Number 724006, Málaga
Investigational Site Number 250007, Nîmes
Investigational Site Number 250002, Toulouse
Investigational Site Number 250004, Rennes
Investigational Site Number 724003, Seville
Investigational Site Number 250010, Nantes
Investigational Site Number 724004, Valencia
Investigational Site Number 724005, Bilbao
Investigational Site Number 250005, Lille
Investigational Site Number 250003, Strasbourg
Investigational Site Number 250001, Lyon Bron
Investigational Site Number 250008, Paris
Investigational Site Number 250006, Nancy
Investigational Site Number 528001, Breda
Investigational Site Number 528002, Rotterdam
Investigational Site Number 724001, Barcelona
Genzyme, a Sanofi Company
INDUSTRY